Pacific Biosciences of California (PACB) Q3 2024 Earnings
PACB·Reported November 7, 2024·After market close
Pacific Biosciences of California reported Q3 2024 revenue of $40.0M, missed analyst consensus of $42.0M by $2.0M. Diluted EPS came in at $-0.22.
Revenue
$40.0Mmissed by $2.0M
Consensus: $42.0MDiluted EPS
$-0.22met estimate
Consensus: $-0.22
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Pacific Biosciences of California's Q3 2024 earnings report.
Pacific Biosciences of California (PACB) reported Q3 2024 earnings on November 7, 2024 after market close.
Pacific Biosciences of California reported revenue of $40.0M and diluted EPS of $-0.22 for Q3 2024.
Revenue missed the consensus estimate of $42.0M by $2.0M. EPS beat the consensus estimate of $-0.22 by $0.00.
You can read the 10-Q periodic report (0001299130-24-000183) directly on SEC EDGAR. The filing index links above go to sec.gov.